| Predicted Trait | |
| Reported Trait | Allergic disease |
| Mapped Trait(s) | allergic disease (MONDO_0005271) |
| Score Construction | |
| PGS Name | PRS135_allergy |
| Development Method | |
| Name | Variants significantly associated with allergic diseases |
| Parameters | p< 3e-8 |
| Variants | |
| Original Genome Build | GRCh37 |
| Number of Variants | 135 |
| Effect Weight Type | beta |
| PGS Source | |
| PGS Catalog Publication (PGP) ID | PGP000184 |
| Citation (link to publication) | Clark H et al. Clin Exp Allergy (2019) |
| Ancestry Distribution | |
| Source of Variant Associations (GWAS) | European: 100% 360,838 individuals (100%) |
| PGS Evaluation | |
| Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
|---|---|---|---|
GWAS Catalog: GCST005038 Europe PMC: 29083406 |
360,838 individuals | European | 12 cohorts
|
|
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
|---|---|---|---|---|---|---|---|---|
| PPM002024 | PSS001008| Ancestry Not Reported| 897 individuals |
PGP000184 | Clark H et al. Clin Exp Allergy (2019) |
Reported Trait: Atopic March | — | — | Relative Risk Ratio (RRR): 1.89 [1.4, 2.55] | — | Only 134 SNPs from the 135 SNP PRS were utilised. Rs10305290 was not included as the SNP was monomorphic. |
| PPM002025 | PSS001007| Multi-ancestry (including European)| 7,242 individuals |
PGP000184 | Clark H et al. Clin Exp Allergy (2019) |
Reported Trait: Atopic March | — | — | Relative Risk Ratio (RRR): 1.99 [1.74, 2.29] | — | For the MAAS cohort, only 134 SNPs from the 135 SNP PRS were utilised. Rs10305290 was not included as the SNP was monomorphic. |
| PPM002026 | PSS001008| Ancestry Not Reported| 897 individuals |
PGP000184 | Clark H et al. Clin Exp Allergy (2019) |
Reported Trait: Persistent eczema and wheeze | — | — | Relative Risk Ratio (RRR): 1.38 [1.01, 1.9] | — | Only 134 SNPs from the 135 SNP PRS were utilised. Rs10305290 was not included as the SNP was monomorphic. |
| PPM002027 | PSS001007| Multi-ancestry (including European)| 7,242 individuals |
PGP000184 | Clark H et al. Clin Exp Allergy (2019) |
Reported Trait: Persistent eczema and wheeze | — | — | Relative Risk Ratio (RRR): 1.39 [1.22, 1.6] | — | For the MAAS cohort, only 134 SNPs from the 135 SNP PRS were utilised. Rs10305290 was not included as the SNP was monomorphic. |
| PPM002028 | PSS001008| Ancestry Not Reported| 897 individuals |
PGP000184 | Clark H et al. Clin Exp Allergy (2019) |
Reported Trait: Persistent eczema with late-onset rhinitis | — | — | Relative Risk Ratio (RRR): 1.35 [1.04, 1.76] | — | Only 134 SNPs from the 135 SNP PRS were utilised. Rs10305290 was not included as the SNP was monomorphic. |
| PPM002029 | PSS001007| Multi-ancestry (including European)| 7,242 individuals |
PGP000184 | Clark H et al. Clin Exp Allergy (2019) |
Reported Trait: Persistent eczema with late-onset rhinitis | — | — | Relative Risk Ratio (RRR): 1.51 [1.35, 1.68] | — | For the MAAS cohort, only 134 SNPs from the 135 SNP PRS were utilised. Rs10305290 was not included as the SNP was monomorphic. |
| PPM002030 | PSS001008| Ancestry Not Reported| 897 individuals |
PGP000184 | Clark H et al. Clin Exp Allergy (2019) |
Reported Trait: Persistent wheeze with late-onset rhinitis | — | — | Relative Risk Ratio (RRR): 1.58 [1.22, 2.03] | — | Only 134 SNPs from the 135 SNP PRS were utilised. Rs10305290 was not included as the SNP was monomorphic. |
| PPM002031 | PSS001007| Multi-ancestry (including European)| 7,242 individuals |
PGP000184 | Clark H et al. Clin Exp Allergy (2019) |
Reported Trait: Persistent wheeze with late-onset rhinitis | — | — | Relative Risk Ratio (RRR): 1.44 [1.3, 1.6] | — | For the MAAS cohort, only 134 SNPs from the 135 SNP PRS were utilised. Rs10305290 was not included as the SNP was monomorphic. |
| PPM002032 | PSS001007| Multi-ancestry (including European)| 7,242 individuals |
PGP000184 | Clark H et al. Clin Exp Allergy (2019) |
Reported Trait: Transient wheeze | — | — | Relative Risk Ratio (RRR): 1.11 [1.02, 1.21] | — | For the MAAS cohort, only 134 SNPs from the 135 SNP PRS were utilised. Rs10305290 was not included as the SNP was monomorphic. |
| PPM002033 | PSS001007| Multi-ancestry (including European)| 7,242 individuals |
PGP000184 | Clark H et al. Clin Exp Allergy (2019) |
Reported Trait: Eczema only | — | — | Relative Risk Ratio (RRR): 1.16 [1.08, 1.24] | — | For the MAAS cohort, only 134 SNPs from the 135 SNP PRS were utilised. Rs10305290 was not included as the SNP was monomorphic. |
| PPM002034 | PSS001008| Ancestry Not Reported| 897 individuals |
PGP000184 | Clark H et al. Clin Exp Allergy (2019) |
Reported Trait: Rhinitis only | — | — | Relative Risk Ratio (RRR): 1.32 [1.06, 1.64] | — | Only 134 SNPs from the 135 SNP PRS were utilised. Rs10305290 was not included as the SNP was monomorphic. |
| PPM002035 | PSS001007| Multi-ancestry (including European)| 7,242 individuals |
PGP000184 | Clark H et al. Clin Exp Allergy (2019) |
Reported Trait: Rhinitis only | — | — | Relative Risk Ratio (RRR): 1.21 [1.12, 1.31] | — | For the MAAS cohort, only 134 SNPs from the 135 SNP PRS were utilised. Rs10305290 was not included as the SNP was monomorphic. |
|
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
|---|---|---|---|---|---|---|---|---|
| PSS001007 | Cases were individuals with latent classes of allergic diseases (LCADs). LCADs includes atopic march (defined as having a high probability of eczema from infancy to age 11 years with increased probability of wheeze overtime. For rhinitis, the probability increases from zero at age 1 year to almost 100% by 8 years. Eczema developed first, followed by wheeze, and then rhinitis) , persistent eczema and wheeze (defined as having a similar probability of wheeze and eczema throughout childhood, likely as co-morbidities, with a low probability of rhinitis throughout childhood), persistent eczema with late‐onset rhinitis (defined as having increased eczema prevalence from ~70% in early life to 95% at age 5 years, with little resolution at 11 years. The probability of rhinitis increases to almost 100% by age 8 years with low probability of wheeze throughout childhood), persistent wheeze with late‐onset rhinitis (definned as having a high probability of wheeze throughout childhood, with increasing probability of rhinitis to almost 100% by age 11 years. Probability of eczema being low, declining steadily at age 11 years), transient wheeze (defined as having a high probability of wheeze within the first 5 years, with remission by age 8 years, and a very low probability of eczema and rhinitis throughout childhood), eczema only (defined as having a high probability of eczema throughout life, peaking at ~80% at age 5 years, then declining steadily to a 50% probability at age 11 years) and rhinitis only (defined as having an increasing probability of rhinitis from age 5 to 11 years, but no wheeze or eczema). Of the 575 cases, 230 had atopic march, 227 had persistent eczema and wheeze, 380 had persistent eczema with late-onset rhinitis, 429 had persistent wheeze with late-onset rhinitis, 599 had transient wheeze, 1089 had eczema only and 791 had rhinitis only. | — | [ ,
51.45 % Male samples |
— | European, NR | European = 6345, NR = 897 | ALSPAC, MAAS | Possible sample overlap (up to 88%) between this dataset and the dataset used to source variants for the PRS. |
| PSS001008 | Cases were individuals with latent classes of allergic diseases (LCADs). LCADs includes atopic march (defined as having a high probability of eczema from infancy to age 11 years with increased probability of wheeze overtime. For rhinitis, the probability increases from zero at age 1 year to almost 100% by 8 years. Eczema developed first, followed by wheeze, and then rhinitis) , persistent eczema and wheeze (defined as having a similar probability of wheeze and eczema throughout childhood, likely as co-morbidities, with a low probability of rhinitis throughout childhood), persistent eczema with late‐onset rhinitis (defined as having increased eczema prevalence from ~70% in early life to 95% at age 5 years, with little resolution at 11 years. The probability of rhinitis increases to almost 100% by age 8 years with low probability of wheeze throughout childhood), persistent wheeze with late‐onset rhinitis (definned as having a high probability of wheeze throughout childhood, with increasing probability of rhinitis to almost 100% by age 11 years. Probability of eczema being low, declining steadily at age 11 years), transient wheeze (defined as having a high probability of wheeze within the first 5 years, with remission by age 8 years, and a very low probability of eczema and rhinitis throughout childhood), eczema only (defined as having a high probability of eczema throughout life, peaking at ~80% at age 5 years, then declining steadily to a 50% probability at age 11 years) and rhinitis only (defined as having an increasing probability of rhinitis from age 5 to 11 years, but no wheeze or eczema). Of the 575 cases, 55 had atopic march, 46 had persistent eczema and wheeze, 73 had persistent eczema with late-onset rhinitis, 81 had persistent wheeze with late-onset rhinitis, 65 had transient wheeze, 141 had eczema only and 114 had rhinitis only. | — | [ ,
53.8 % Male samples |
— | Not reported | — | MAAS | — |